

**RECEIVED
CENTRAL FAX CENTER**

JAN 08 2008

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below.

Dated: January 8, 2008

Signature:


(Pamela A. Harrison)Docket No.: SLII-P01-002
(PATENT)**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:
Hooft Van Huijsduijnen et al.

Application No.: 10/526,164

Confirmation No.: 2570

Filed: August 24, 2005

Art Unit: 1654

For: PROTEIN TYROSINE PHOSPHATASE
INHIBITORS

Examiner: J. Ha

RESPONSE TO RESTRICTION REQUIREMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the restriction requirement set forth in the Office Action mailed November 27, 2007, Applicants hereby provisionally elect Group 16 (claim 53) for continued examination, with traverse.

The Examiner has also required two species elections for search purposes for the claim of Group 16. For the sequence, Applicants elect the amino acid sequence of SEQ ID NO:2, EFYGAF A, for search purposes *only*. For the cancer, Applicants elect cancer of the intestine for search purposes *only*. Claim 53 reads on the elected species.

Applicants respectfully traverse the Restriction Requirement. The Examiner alleges that the inventions lists as Groups 1-23 do not relate to a single general inventive concept because they lack the same or corresponding special technical features. The Examiner states that Dente *et al.* (J. Mol Biol. 269:694-703 (1997)) teaches a peptide, EFYGT YGLP that meet the limitation of claim 1 (Applicants assume the Examiner intended this to mean claim 26, as claim 1 was previously cancelled) and invention 1. This is incorrect. While the sequence identified by the Examiner

10859501_1.DOC